WASHINGTON — The Food and Drug Administration (FDA) announced on Wednesday that it will assemble an external panel of advisers to evaluate whether compounding pharmacies should be permitted to produce certain peptides. The discussions are scheduled for July 23 and 24, with another session planned before the end of February 2027.
In 2023, the FDA excluded 19 peptides from the list of drugs that compounding pharmacies are authorized to manufacture. The July panel will explore the possibility of reinstating seven of these peptides. A future meeting, which is yet to be scheduled, will consider adding five more.
Although there is limited data on the safety and efficacy of many peptides, they have gained popularity, often endorsed by online influencers and health secretary Robert F. Kennedy Jr. This review follows Kennedy’s discussion with podcaster Joe Rogan in February, where he expressed a desire to increase accessibility to these peptides.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
